HDACs and Their Inhibitors on Post-Translational Modifications: The Regulation of Cardiovascular Disease
Cells · 20.07.2025 · 14 (14) · 1116
DOI: 10.3390/cells14141116 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 20.07.2025. Verfasst von Siyi Yang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biochemistry, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Xiasha High-Tech Zone No.2 Road, Hangzhou 310018, Chi…. Hauptthemen laut MEDLINE: Protein Processing, Post-Translational, Histone Deacetylase Inhibitors, Cardiovascular Diseases, Histone Deacetylases. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 210 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cardiovascular diseases (CVD), such as myocardial hypertrophy, heart failure, atherosclerosis, and myocardial ischemia/reperfusion (I/R) injury, are among the major threats to human health worldwide. Post-translational modifications alter the function of proteins through dynamic chemical modification after synthesis. This mechanism not only plays an important role in maintaining homeostasis and plays a crucial role in maintaining normal cardiovascular function, but is also closely related to the pathological state of various diseases. Histone deacetylases (HDACs) play an important role in the epigenetic regulation of gene expression, and play important roles in post-translational modification by catalyzing the deacetylation of key lysine residues in nucleosomal histones, which are closely associated with the occurrence and development of cardiovascular diseases. Recent studies indicate that HDAC inhibitors (HDACis) may represent a new class of drugs for the treatment of cardiovascular diseases by influencing post-translational modifications. In this review, we systematically summarize the mechanism of action of HDACs and HDACis in post-translational modifications related to common cardiovascular diseases, providing new ideas for the treatment of CVD, and explore possible future research directions on the relationship between HDAC and HDACi in post-translational modifications and cardiovascular diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Biochemistry, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Xiasha High-Tech Zone No.2 Road, Hangzhou 310018, China.
- Zhejiang Provincial Key Laboratory of Silkworm Bioreactor and Biomedicine, Hangzhou 310018, China.
ORCID-Profile: Yidong Sun
Zitieren
APA
Yang, S., Sun, Y., & Yu, W. (2025). HDACs and Their Inhibitors on Post-Translational Modifications: The Regulation of Cardiovascular Disease. Cells, 14(14), 1116. https://doi.org/10.3390/cells14141116
Vancouver
Yang S, Sun Y, Yu W. HDACs and Their Inhibitors on Post-Translational Modifications: The Regulation of Cardiovascular Disease. Cells. 2025;14(14):1116. doi:10.3390/cells14141116
BibTeX
@article{Yang2025,
author = {Yang, Siyi and Sun, Yidong and Yu, Wei},
title = {HDACs and Their Inhibitors on Post-Translational Modifications: The Regulation of Cardiovascular Disease},
journal = {Cells},
year = {2025},
volume = {14},
number = {14},
pages = {1116},
doi = {10.3390/cells14141116}
}
EUVIMED